ARF6 and renal pelvis/ureter urothelial carcinoma: In conclusion, this work underlined that the downregulation of miR-145-5p could be a biomarker of disease-free survival or cancer-specific survival in the UTUC asset; in parallel, the study hypothesized that miR-145 therapies and other ARF6-targeting inhibitors could be novel promising drugs for UTUC patients [208].